Can We Manage Presymptomatic TTR V142I Related Risk?

JACC Heart Fail. 2022 Feb;10(2):139-141. doi: 10.1016/j.jchf.2021.10.009. Epub 2021 Dec 8.

Authors

Michael F Murray¹, Edward J Miller²

Affiliations

¹ Department of Genetics, Yale University School of Medicine, New Haven, Connecticut, USA. Electronic address: michael.murray@yale.edu.
² Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.

PMID: 35115087
DOI: 10.1016/j.jchf.2021.10.009

No abstract available

Keywords: DNA-based screening; TTR V122I; TTR V142I; hs-TnI; myocardial injury; transthyretin cardiac amyloidosis.

Publication types

Editorial
Comment

MeSH terms

Adult
Amyloid Neuropathies, Familial*
Heart
Heart Failure*
Humans
Prealbumin
Ventricular Remodeling

Substances

Prealbumin